ArticleParkinson's disease2014
Cognitive Status Correlates with CXCL10/IP-10 Levels in Parkinson's Disease.
Article in Parkinson's disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Association between Periodontal Disease and Cognitive Impairment in Adults.International journal of environmental research and public health · 2023Pooled it
- Inflammatory markers and depression in Parkinson's disease: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Pooled it
- Epigenetic Signatures in an Italian Cohort of Parkinson's Disease Patients from Sicily.Brain sciences · 2025Article
- Epigenetic dysregulation of transposable elements in cognitive impairment and Alzheimer's disease.GeroScience · 2025Article
- Isomeric 3-Pyridinylmethylcoumarins Differ in Erk1/2-Inhibition and Modulation of BV2 Microglia-Mediated Neuroinflammation.Molecules (Basel, Switzerland) · 2025Article
- AR71, Histamine HInternational journal of molecular sciences · 2024Article
- Associations Between Neuropsychiatric Symptoms and Inflammation in Neurodegenerative Dementia: A Systematic Review.Journal of inflammation research · 2024Review
- Alteration of Blood Immune Biomarkers in MCI Patients with DifferentInternational journal of molecular sciences · 2023Article
- Modulating neuroinflammation in neurodegeneration-related dementia: can microglial toll-like receptors pull the plug?Metabolic brain disease · 2021Review
- Soluble CD163 Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021Article
- IP10, KC and M-CSF Are Remarkably Increased in the Brains from the Various Strains of Experimental Mice Infected with Different Scrapie Agents.Virologica Sinica · 2020Article
- Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?Frontiers in neurology · 2019Review
- Palm Fruit Bioactives modulate human astrocyte activity in vitro altering the cytokine secretome reducing levels of TNFα, RANTES and IP-10.Scientific reports · 2018Article
- Dysregulation of C-X-C motif ligand 10 during aging and association with cognitive performance.Neurobiology of aging · 2018Article
- Anti-Inflammatory and Neuroprotective Effects of PGEJournal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2017Article
- Methyl donor supplementation alters cognitive performance and motivation in female offspring from high-fat diet-fed dams.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2017Article
- Distinct Cytokine and Chemokine Profiles in Autism Spectrum Disorders.Frontiers in immunology · 2017Article
- Converging mediators from immune and trophic pathways to identify Parkinson disease dementia.Neurology(R) neuroimmunology & neuroinflammation · 2016Article
- Exploring the Homeostatic and Sensory Roles of the Immune System.Frontiers in immunology · 2016Review
- Lenalidomide reduces microglial activation and behavioral deficits in a transgenic model of Parkinson's disease.Journal of neuroinflammation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment and depressive symptoms are of great interest in Parkinson's disease (PD), since they are very common and lead to increased disability with poor quality of life. Inflammatory mechanisms have been implicated in PD and its nonmotor symptoms. In the current pilot study, we aimed to evaluate plasma levels of chemokines in PD patients and to analyze the putative association of chemokines with depressive symptoms and cognitive performance. We hypothesized that higher chemokines levels are associated with worse cognitive performance and increased depressive symptoms in PD. For this purpose, 40 PD patients and 25 age- and gender-matched controls were subjected to a clinical evaluation including cognitive and mood tests. Peripheral blood was drawn and plasma levels of CCL2/MCP-1, CCL11/eotaxin, CCL24/eotaxin-2, and CXCL10/IP-10 were measured by enzyme-linked immunosorbent assay. PD patients and control individuals presented comparable plasma concentrations of all the evaluated chemokines. In PD patients, CXCL10/IP-10 plasma levels correlated positively with Hoehn and Yahr staging scale. In addition, the higher CXCL10/IP-10 levels, the worse performance on cognitive tests. Although there was no significant difference between PD patients and control individuals regarding chemokines levels, our preliminary results showed that CXCL10/IP-10 may be associated with cognitive status in PD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.